adalimumab

Ligand id: 4860

Name: adalimumab

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: adalimumab

Classification
Compound class Antibody
Approved drug? Yes (FDA (2002), EMA (2003))
International Nonproprietary Names
INN number INN
7860 adalimumab
Synonyms
D2E7 [5] | FKB327 | Humira®
Database Links
Specialist databases
IMGT/mAb-DB 165
Other databases
GtoPdb PubChem SID 178101561
PubChem SID 178101561
Search PubMed clinical trials adalimumab
Search PubMed titles adalimumab
Search PubMed titles/abstracts adalimumab
Wikipedia Adalimumab
Comments
Adalimumab is an anti-TNFα monoclonal antibody with immunosuppresive activity [5]. It was the first fully human monoclonal antibody drug approved by the FDA.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.

Biosimilars:
In September 2016, the US FDA approved Amjevita® (ZRC-3197 [1], adalimumab-atto) as a biosimilar to Humira® for multiple inflammatory diseases covered by the reference product label [3].
Boehringer Ingelheim Pharmaceuticals' adalimumab-adbm (Cyltezo®) was FDA approved in August 2017.
Additional adalimumab biosimilars such as ABP 501 (Amgen; NCT01970475), SB5 (Samsung Bioepis; NCT02167139), BCD-057 (Biocad; NCT02762955), GP2017 (Sandoz; NCT02016105), M923 (Momenta Pharmaceuticals; NCT02581345), MYL-1401A (Mylan; NCT02714322) and PF-06410293 (Pfizer; NCT02480153) are all in Phase 3 development.
FKB327 from Fujifilm Kyowa Kirin Biologics (NCT02260791) was recently described in BJCP [6].
IBI303 (Innovent Biologics) is beginning Phase 3 evaluation for active ankylosing spondylitis (see NCT02893254).